MondegarAI
Propel Bio Management, LLC

Q1 2026 · 13F-HR

Propel Bio Management, LLCholdings as filed

Filed 2026-05-14 · accession 0000898432-26-000369

$158.7M
Reported value
38
Positions
2026-03-31
Period end
View analyzed profile →PRO

The Brief · Propel Bio Management, LLC · Q1 2026

AI · grounded in 13F

Propel Bio Management, LLC established a new position in CORT worth $6.02M. The fund also opened new stakes in VOR for $5.59M and OBIO for $3.83M. On the sell side, the manager closed its position in NKTR, reducing exposure by $3.5M.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
72651A207PAGPPLAINS GP HLDGS L P$30.2M19.0%1,272,360CommonSHARED
004468500ACHVACHIEVE LIFE SCIENCES INC$11.4M7.17%3,786,425CommonSOLE
71722W107PHATPHATHOM PHARMACEUTICALS INC$9.4M5.90%841,272CommonSOLE
24661P807DCTHDELCATH SYS INC$9.2M5.77%979,698CommonSOLE
218352102CORTCORCEPT THERAPEUTICS INC$6.0M3.80%147,828CommonSOLE
00289Y206ABEOABEONA THERAPEUTICS INC$6.0M3.79%1,329,899CommonSOLE
929033207VORVOR BIOPHARMA INC$5.6M3.52%314,543CommonSOLE
501976104KYTXKYVERNA THERAPEUTICS INC$5.6M3.52%644,421CommonSOLE
59935V107MISTMILESTONE PHARMACEUTICALS IN$5.1M3.20%4,118,321CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC NEW$4.1M2.61%131,364CommonSHARED
20451W101CMPSCOMPASS PATHWAYS PLC$4.1M2.60%742,049CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$4.1M2.58%210,163CommonSOLE
46124U107IVAINVENTIVA SA$4.0M2.52%724,678CommonSOLE
78397T202SABSSAB BIOTHERAPEUTICS INC$3.9M2.45%1,012,790CommonSOLE
68572M106OBIOORCHESTRA BIOMED HLDGS INC$3.8M2.41%896,701CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$3.6M2.26%380,420CommonSOLE
H5870P102OCSOCULIS HOLDING AG$3.3M2.07%122,223CommonSHARED
67576A100OCULOCULAR THERAPEUTIX INC$3.2M2.03%382,375CommonSOLE
91678A107UPBUPSTREAM BIO INC$3.1M1.95%341,779CommonSOLE
03843E104AQSTAQUESTIVE THERAPEUTICS INC$3.0M1.86%710,988CommonSOLE
30233G209EYPTEYEPOINT INC$2.8M1.76%215,825CommonSOLE
89532M101TRVITREVI THERAPEUTICS INC$2.6M1.67%223,802CommonSOLE
488445206ZVRAZEVRA THERAPEUTICS INC$2.6M1.66%282,418CommonSOLE
4525EP101VTLUSDIMMUNIC INC$2.6M1.65%2,344,779CommonSOLE
19249H103CHRSCOHERUS ONCOLOGY INC$2.4M1.52%1,420,550CommonSOLE
690469101OVIDOVID THERAPEUTICS INC$2.0M1.28%921,457CommonSOLE
696389402PALIPALISADE BIO INC$2.0M1.26%1,115,000CommonSOLE
482929106KLRSKALARIS THERAPEUTICS INC$1.7M1.08%295,771CommonSOLE
N90064101QUREUNIQURE NV$1.7M1.08%104,772CommonSOLE
04746L203LONALEONABIO INC$1.5M0.94%149,279CommonSHARED
67080N101NUVBNUVATION BIO INC$1.4M0.89%329,296CommonSOLE
578784100MAZEMAZE THERAPEUTICS INC$1.3M0.82%43,798CommonSOLE
30054Y107EVMNEVOMMUNE INC$1.3M0.81%55,664CommonSOLE
221015100CRVSCORVUS PHARMACEUTICALS INC$1.3M0.79%85,791CommonSOLE
01438T106ALDXALDEYRA THERAPEUTICS INC$1.2M0.78%730,606CommonSOLE
04317A107ARTVARTIVA BIOTHERAPEUTICS INC$949,8180.60%146,369CommonSOLE
G23549101CNTBCONNECT BIOPHARMA HLDGS LTD$553,9090.35%209,493CommonSOLE
80401L803MSLESATELLOS BIOSCIENCE INC$57,1160.04%10,145CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.